News Feed
News
1478 results
Trends of incident stimulant use disorder diagnoses before and after the COVID-19 pandemic in British Columbia (2013-2024): a population-based study
BackgroundThere is rising detection of unregulated stimulants (e.g. cocaine and methamphetamine) in toxicology results among people who died of unregulated drug poisoning. Nevertheless, little research describes the population-level trends of incident (new) stimulant use disorder (StUD) diagnoses. This study reports…
Identifying clinical features associated with electroconvulsive therapy response in adolescents with major depressive disorder using machine learning
BackgroundElectroconvulsive therapy (ECT) is an effective treatment for adolescent major depressive disorder (MDD), but its efficacy varies. This study utilized machine learning (ML) to identify baseline clinical factors associated with poor ECT response.MethodsWe retrospectively enrolled 503 adolescent MDD patients. A…
Beyond distress relief: the Anhedonic Subtype of nonsuicidal self-injury and the imperative for Positive Affect Treatment
This perspective article argues that the theoretical landscape of nonsuicidal self-injury (NSSI) has long been stabilized by the “hydraulic” model of Automatic Negative Reinforcement, which conceptualizes self-harm primarily as a mechanism to down-regulate aversive hyper-arousal. While this framework successfully elucidates…
Resonance across cultures and faiths: examining the violin music’s role in emotional, psychological, and spiritual well-being for sustainable societies
Music is a decisive factor of the everyday life and the core focus of human being of any culture. People of all ages, races and ethnicities prefer to listen to it and play it. But music is not only entertainment…
Newcomer anti-IL-33 makes strides in COPD
Nature Biotechnology, Published online: 07 May 2026; doi:10.1038/s41587-026-03136-xAstraZeneca’s IL-33 antibody tozorakimab targets two distinct signaling pathways engaged in COPD: inflammation and epithelial dysfunction.
The Download: the tech reshaping IVF and the rise of balcony solar
This is today’s edition of The Download, our weekday newsletter that provides a daily dose of what’s going on in the world of technology. What’s next for IVF IVF has brought millions of babies into the world over the last…
STAT+: FDA to reconsider treatment for rare cancer after its surprise rejection
The companies developing Ebvallo reached an agreement with the FDA to address its main reason for rejecting the drug.
Hospital shootings steadily increased since 2000
What the FDA has lost, why hantavirus isn't the next pandemic, and more health news from Morning Rounds
STAT+: Next-gen Duchenne drug from Entrada disappoints
A next-gen Duchenne therapy from Entrada Therapeutics fell short in an early study, as a number of companies race to make improved drugs.
STAT+: Color me skeptical: Drinking gold is not an ALS cure
In this week's Biotech Scorecard newsletter, Adam Feuerstein takes on the company touting gold microdust suspended in water as an ALS treatment.
The balcony solar boom is coming to the US
Dozens of US states are considering legislation to allow people to install plug-in solar systems, often called balcony solar. These small arrays require little to no setup and could help cut emissions and power bills. Balcony solar is already popular…
What’s next for IVF
MIT Technology Review’s What’s Next series looks across industries, trends, and technologies to give you a first look at the future. You can read the rest of them here. Forty-eight years ago this July, Louise Joy Brown became the world’s first…
STAT+: Angelini Pharma buys Catalyst Pharmaceuticals and its rare disease drugs for $4.1B
The Italian firm Angelini Pharma is buying Catalyst Pharmaceuticals, the maker of rare disease drugs, for $4.1 billion.
[Articles] Who receives psychiatry-focused pharmacogenomic testing, and is it associated with prescribing patterns and acute care utilisation in depression? Real-world evidence from a large health system
In routine clinical practice, PGx testing is preferentially used in youth and adults with clinically complex histories and is associated with shifts in antidepressant prescribing patterns. Exploratory findings suggest hypothesis-generating signals of reduced psychiatric ED utilisation among patients with higher…
An Exploratory Study on the Prediction of Recurrence Risk of Bipolar Disorder Using Sentiment Analysis Technology Based on Multi-modal Feature Fusion
Conditions: Bipolar Disorder (BD); Healthy Control Interventions: Other: This is an observational study with no intervention. Sponsors: Shanghai Mental Health Center Recruiting
A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder
Conditions: Depressive Disorder, Major Interventions: Drug: Seltorexant; Drug: Placebo Sponsors: Janssen Research & Development, LLC Not yet recruiting
Pupillometry in Identifying Risk of Postoperative Opioid-induced Respiratory Depression in Children Undergoing Tonsillectomy
Conditions: Opioid-Induced Respiratory Depression; Postoperative Complications (Cardiopulmonary); Respiratory Complications Due to Anesthesia Interventions: Device: Infrared Pupillometry Sponsors: NeurOptics Inc; National Institute on Drug Abuse (NIDA); University of Pittsburgh Medical Center; University of California, San Francisco Not yet recruiting
tDCS: Sleep to Mood in Depression (S2M-D)
Conditions: Major Depressive Disorder; MDD; Depression; Major Depressive Episode Interventions: Device: transcranial direct current stimulation (tDCS) Sponsors: NYU Langone Health; Zabara Foundation Not yet recruiting
Oral small-molecule GLP-1 drugs penetrate deep into the brain to suppress cravings
NIH-funded research identifies new mechanism of action for next-generation weight-loss drugs
NIH-funded study suggests that testosterone suppresses brain tumor growth in males
Findings may warrant exploration of the hormones as glioblastoma treatment